NLRP3 and colitis: Some studies have also found that NLRP1b, NLRP3, and pyrin protected against colorectal cancer by facilitating the secretion of IL-18 to promote epithelial barrier regeneration during the early stages of colorectal cancer.283,284,291–294 Although DSS-treated mice with loss of inflammasome are generally more likely to develop colitis than wild-type mice, the results may be different on specific NLRPs.